176 related articles for article (PubMed ID: 36064940)
1. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.
Reincke M; Schultheiss M; Doppler M; Verloh N; Uller W; Sturm L; Thimme R; Goetz C; Bettinger D
Hepatol Commun; 2022 Nov; 6(11):3223-3233. PubMed ID: 36064940
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
3. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
4. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
5. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
8. Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study.
Carrión L; Clemente-Sánchez A; Márquez-Pérez L; Orcajo-Rincón J; Rotger A; Ramón-Botella E; González-Leyte M; Echenagusía-Boyra M; Luis Colón A; Reguera-Berenguer L; Bañares R; Rincón D; Matilla-Peña A
Therap Adv Gastroenterol; 2023; 16():17562848231206995. PubMed ID: 37920686
[TBL] [Abstract][Full Text] [Related]
9. Albumin-Bilirubin Score: An Accurate Predictor of Hepatic Decompensation in High-Risk Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma.
Mohammed MAA; Khalaf MH; Liang T; Wang DS; Lungren MP; Rosenberg J; Kothary N
J Vasc Interv Radiol; 2018 Nov; 29(11):1527-1534.e1. PubMed ID: 30274856
[TBL] [Abstract][Full Text] [Related]
10. Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis.
Navadurong H; Thanapirom K; Wejnaruemarn S; Prasoppokakorn T; Chaiteerakij R; Komolmit P; Treeprasertsuk S
World J Gastroenterol; 2023 Aug; 29(32):4873-4882. PubMed ID: 37701131
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
[TBL] [Abstract][Full Text] [Related]
12. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
[TBL] [Abstract][Full Text] [Related]
13. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
14. Chronic Hepatotoxicity in Patients with Metastatic Neuroendocrine Tumor: Transarterial Chemoembolization versus Transarterial Radioembolization.
Currie BM; Nadolski G; Mondschein J; Dagli M; Sudheendra D; Stavropoulos SW; Soulen MC
J Vasc Interv Radiol; 2020 Oct; 31(10):1627-1635. PubMed ID: 33004146
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
16. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
Pinato DJ; Sharma R; Allara E; Yen C; Arizumi T; Kubota K; Bettinger D; Jang JW; Smirne C; Kim YW; Kudo M; Howell J; Ramaswami R; Burlone ME; Guerra V; Thimme R; Ishizuka M; Stebbing J; Pirisi M; Carr BI
J Hepatol; 2017 Feb; 66(2):338-346. PubMed ID: 27677714
[TBL] [Abstract][Full Text] [Related]
17. Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion.
McGee HM; King MJ; Özbek U; Olson A; Kim E; Fischman AM; Schwartz M; Rosenzweig KE; Buckstein M
Am J Clin Oncol; 2019 Apr; 42(4):367-374. PubMed ID: 30724782
[TBL] [Abstract][Full Text] [Related]
18. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.
Yoo SH; Jang JW; Kwon JH; Jung SM; Jang B; Choi JY
Clin Mol Hepatol; 2016 Dec; 22(4):458-465. PubMed ID: 28081589
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization of hepatocarcinoma with
Chiesa C; Mira M; Bhoori S; Bormolini G; Maccauro M; Spreafico C; Cascella T; Cavallo A; De Nile MC; Mazzaglia S; Capozza A; Tagliabue G; Brusa A; Marchianò A; Seregni E; Mazzaferro V
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3018-3032. PubMed ID: 32451604
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
Gui B; Weiner AA; Nosher J; Lu SE; Foltz GM; Hasan O; Kim SK; Gendel V; Mani NB; Carpizo DR; Saad NE; Kennedy TJ; Zuckerman DA; Olsen JR; Parikh PJ; Jabbour SK
Am J Clin Oncol; 2018 Sep; 41(9):861-866. PubMed ID: 28418940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
